Biodegradable Particles as Vaccine Delivery Systems: Size Matters

被引:190
作者
Joshi, Vijaya B. [1 ]
Geary, Sean M. [1 ]
Salem, Aliasger K. [1 ]
机构
[1] Univ Iowa, Coll Pharm, Dept Pharmaceut Sci & Expt Therapeut, Iowa City, IA 52242 USA
基金
美国国家卫生研究院;
关键词
CpG ODN; cytotoxic T lymphocytes; dendritic cells; nanoparticles; poly (lactide-co-glycolide); vaccine; IN-VITRO UPTAKE; DENDRITIC CELLS; T-CELL; IMMUNE-RESPONSES; IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES; CROSS-PRESENTATION; ANTIGEN DELIVERY; CPG MOTIFS; NANOPARTICLES; MICROSPHERES;
D O I
10.1208/s12248-012-9418-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Poly(lactide-co-glycolide) (PLGA) particles have strong potential as antigen delivery systems. The size of PLGA particles used to vaccinate mice can affect the magnitude of the antigen-specific immune response stimulated. In this study, we fabricated and characterized 17 mu m, 7 mu m, 1 mu m, and 300 nm PLGA particles coloaded with a model antigen ovalbumin (OVA) and CpG oligodeoxynucleotides (CpG ODN). PLGA particles demonstrated a size-dependent burst release followed by a more sustained release of encapsulated molecules. PLGA particles that were 300 nm in size showed the highest internalization by, and maximum activation of, dendritic cells. The systemic antigen-specific immune response to vaccination was measured after administration of two intraperitoneal injections, 7 days apart, of 100 mu g OVA and 50 mu g CpG ODN in C57BL/6 mice. In vivo studies showed that 300 nm sized PLGA particles generated the highest antigen-specific cytotoxic T cell responses by days 14 and 21. These mice also showed the highest IgG2a:IgG1 ratio of OVA-specific antibodies on day 28. This study suggests that the smaller the PLGA particle used to deliver antigen and adjuvants the stronger the antigen-specific cytotoxic T cell response generated.
引用
收藏
页码:85 / 94
页数:10
相关论文
共 37 条
[1]  
[Anonymous], 1995, ENCY HDB BIOMATERIAL
[2]   Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro [J].
Audran, R ;
Peter, K ;
Dannull, J ;
Men, Y ;
Scandella, E ;
Groettrup, M ;
Gander, B ;
Corradin, G .
VACCINE, 2003, 21 (11-12) :1250-1255
[3]   Immunology and immunotherapy of human cancer: present concepts and clinical developments [J].
Bremers, AJA ;
Parmiani, G .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 34 (01) :1-25
[4]   Liposomal delivery of CTL epitopes to dendritic cells [J].
Chikh, G ;
Schutze-Redelmeir, MP .
BIOSCIENCE REPORTS, 2002, 22 (02) :339-353
[5]   In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localisation [J].
Coester, C ;
Nayyar, P ;
Samuel, J .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2006, 62 (03) :306-314
[6]   Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles:: effect of formulation and route of immunization on induction of Th1 and Th2 cells [J].
Conway, MA ;
Madrigal-Estebas, L ;
McClean, S ;
Brayden, DJ ;
Mills, KHG .
VACCINE, 2001, 19 (15-16) :1940-1950
[7]   Nanotechnology: Intelligent design to treat complex disease [J].
Couvreur, Patrick ;
Vauthier, Christine .
PHARMACEUTICAL RESEARCH, 2006, 23 (07) :1417-1450
[8]   Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells [J].
Elamanchili, P ;
Diwan, M ;
Cao, M ;
Samuel, J .
VACCINE, 2004, 22 (19) :2406-2412
[9]   Pathogen-mimicking nanoparticles for vaccine delivery to dendritic cells [J].
Elamanchili, Praveen ;
Lutsiak, Christine M. E. ;
Hamdy, Samar ;
Diwan, Manish ;
Samuel, John .
JOURNAL OF IMMUNOTHERAPY, 2007, 30 (04) :378-395
[10]   Vaccines that facilitate antigen entry into dendritic cells [J].
Gamvrellis, A ;
Leong, D ;
Hanley, JC ;
Xiang, SD ;
Mottram, P ;
Plebanski, M .
IMMUNOLOGY AND CELL BIOLOGY, 2004, 82 (05) :506-516